Work

PD-7 Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma (aHCC) and previously treated gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ): Results of the COSMIC-021 study

Year: 2022

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2022.04.085

Authors: D. Li, Y. Loriot, A. Burgoyne, J. Cleary, A. Santoro, D. Lin, S. Ponce Aix, I. Garrido-Laguna, R. Sudhagoni, J. Lougheed, S. Andrianova, S. Paulson

Institutions: City Of Hope National Medical Center, City of Hope, Inserm, Université Paris-Saclay, Institut Gustave Roussy, University of California San Diego, Moores Cancer Center, Harvard University, Dana-Farber Cancer Institute, Humanitas University, IRCCS Humanitas Research Hospital, Thomas Jefferson University, Sidney Kimmel Cancer Center, Universidad Complutense de Madrid, Spanish National Cancer Research Centre, Hospital Universitario 12 De Octubre, Huntsman Cancer Institute, Exelixis (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Roche, Exelixis

OpenAlex ID: W4283781518

FWCI:

Cites:

Cited by:

Related to: 10